La tromboaspiración se correlaciona con un menor índice de resistencia de la microcirculación. Dr. Dejan Orlic, MD. Congreso euroPCR 2013, Paris, Francia. Encuentre más presentaciones en la web de SOLACI: www.solaci.org/
Lo mejor del ACC 2015 (San Diego)
Miércoles, 18/3/15 De 14:00 a 15:30
Casa del Corazón. Sociedad Española de Cardiología.
http://acc15.secardiologia.es/
Arritmias/Insuficiencia cardiaca
Dr. Romàn Freixa Pamias
Servicio de Cardiología. Hospital Moisés Broggi, Barcelona
Lo mejor del ACC 2015 (San Diego)
Miércoles, 18/3/15 De 14:00 a 15:30
Casa del Corazón. Sociedad Española de Cardiología.
http://acc15.secardiologia.es/
Arritmias/Insuficiencia cardiaca
Dr. Romàn Freixa Pamias
Servicio de Cardiología. Hospital Moisés Broggi, Barcelona
Lo mejor del Congreso ACC Chicago 2016
06/04/16 14:00 - 15:30h Casa del Corazón, Madrid
http://acc16.secardiologia.es
Lo mejor en cardiopatía isquémica e intervencionismo
Dr. Marcelo Sanmartín Fernández, Hospital Universitario Ramón y Cajal, Madrid
@ImMSanFer
In detail review of principles of nuclear medicine and their application in cardiology. Up to date protocols and techniques with guidelines of the use of imaging techniques in different clinical situations.
Linee guida e timing chirurgico insufficienza aorticaICARDIOLOGI
Linee guida e timing chirurgico dell’insufficienza valvolare aortica: che cosa attende migliore definizione. Dr. Antonio Federico - Villa Maria Cecilia Hospital - Maggio 2009
Lo mejor del Congreso ACC Chicago 2016
06/04/16 14:00 - 15:30h Casa del Corazón, Madrid
http://acc16.secardiologia.es
Lo mejor en insuficiencia cardiaca. #postACC16.
Dr. Alfonso Valle Muñoz, Hospital General Universitario Marina Alta, Denia (Alicante)
@ValleAlfonso
Management of Massive & Submassive Pulmonary EmbolismSun Yai-Cheng
AHA Scientific Statement
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
Circulation 2011, 123:1788-1830
Lo mejor del Congreso ACC Chicago 2016
06/04/16 14:00 - 15:30h Casa del Corazón, Madrid
http://acc16.secardiologia.es
Lo mejor en cardiopatía isquémica e intervencionismo
Dr. Marcelo Sanmartín Fernández, Hospital Universitario Ramón y Cajal, Madrid
@ImMSanFer
In detail review of principles of nuclear medicine and their application in cardiology. Up to date protocols and techniques with guidelines of the use of imaging techniques in different clinical situations.
Linee guida e timing chirurgico insufficienza aorticaICARDIOLOGI
Linee guida e timing chirurgico dell’insufficienza valvolare aortica: che cosa attende migliore definizione. Dr. Antonio Federico - Villa Maria Cecilia Hospital - Maggio 2009
Lo mejor del Congreso ACC Chicago 2016
06/04/16 14:00 - 15:30h Casa del Corazón, Madrid
http://acc16.secardiologia.es
Lo mejor en insuficiencia cardiaca. #postACC16.
Dr. Alfonso Valle Muñoz, Hospital General Universitario Marina Alta, Denia (Alicante)
@ValleAlfonso
Management of Massive & Submassive Pulmonary EmbolismSun Yai-Cheng
AHA Scientific Statement
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
Circulation 2011, 123:1788-1830
Conferencia magistral "20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia y evolución de las redes de infarto" del Dr. Petr Widimsky durante la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
http://www.theheart.org/web_slides/1364595.do
A study on Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) designed to determine whether vopaxar, when added to existing standard of care (eg, aspirin, clopidogrel) for preventing MI and stroke in patients with ACS, will provide additional benefit.
Estimulación cardiaca sin cables
08/10/2015 13:30-15:00h Casa del Corazón, Madrid
http://marcapasossincables.secardiologia.es
#marcapasossincables
La estimulación sin cables: resultados a medio plazo
Dr. Lluís Mont Girbau, Hospital Clínic (Barcelona)
@Montgirbau
Presentación de la ponencia "Oclusión Crónica Total (CTO): Intervención Coronaria Percutánea (ICP) vs Tratamiento Médico Óptimo (TMO)" realizada por Tomás Benito González para foroepic.org en los Diálogos EPIC_Cierre Percutáneo de la Orejuela Izquierda el 15 de Marzo de 2018 en Madrid (España)
Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.Cristiano Amarelli
The ALMA score from Loforte et al. presented at the ASAIO meeting in Chicago on June 24th. An Useful Decision Supporting Tool available bedside to predict right ventricular failure and even to modify the surgical planning to support/protect right heart and warranting better outcome.
Dra. Margaret Redfield. Congreso ACC 2013, Estados Unidos. RELAX: Inhibidor de la fosfodiesterasa-5 no mostró beneficio en la insuficiencia cardiaca con función ventricular preservada. Encuentre más presentaciones de este congreso en la página oficial de SOLACI: www.solaci.org/
Manejo peri-procedimiento en el paciente con PCI. Dr. Lluberas, Ricardo. Congreso SOLACI 2012, México. Encuentre más presentaciones en la web: www.solaci.org/
Disclosures: Full time employee of Abbott Vascular. Dra. Moreira Rebeca.SOLACI México Congress 2012. Find more presentations on the web site: www.solaci.org/
Reestenosis, Síndrome coronario agudo. Rol actual de los nuevos antiplaquetarios en el síndrome coronario agudo. Congreso SOLACI Chile 2011.Dr. Ramón Corbalán. Encuentre más presentaciones en la página www.solaci.org/
SOLACI Chile Congress 2011. Dr.Ajay Kirtane. Drug-Eluting Stents for Multivessel PCI: Indications and Outcomes. Find more presentations on the web site: www.solaci.org/
SOLACI Coverage: AHA 2012 Congress. Dr. Jay H. Traverse. Estudio TIME: Uso y duración de la infusión de células madre derivadas de médula ósea en la disfunción ventricular izquierda después de un infarto de miocardio.Find more presentations on our web http://solaci.org/es/aha_2012.php
SOLACI Coverage: AHA 2012 Congress. Dr. Esteban Lopez-de-Sa . PILOT trial: El estudio piloto de dos niveles de hipotermia en los sobrevivientes comatosos tras un paro cardiaco fuera del hospital. Find more presentations on our web http://solaci.org/es/aha_2012.php
Estudio presentado por el Dr. Gilles Montalescot en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
Estudio presentado por la Dra. Anna Toso en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
More from Sociedad Latinoamericana de Cardiología Intervencionista (20)
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Tromboaspiración: resistencia de la microcirculación
1. The randomized physiologic
assessment of thrombus aspiration
in patients with ST-segment
elevation myocardial infarction trial
PATA-STEMI study
Dejan Orlic, MD on behalf of PATA STEMI
investigators
Clinical center of Serbia
Belgrade, Serbia
2. Potential conflicts of interest
Speaker's name: Dejan Orlic
I do not have any potential conflict of interest
3. Background and aim
• Routine thrombus aspiration is superior to
conventional PPCI in terms of improved
myocardial perfusion in patients with STEMI
• However, myocardial perfusion after thrombus
aspiration has not been evaluated by a
quantitative, invasive method, such as determining
the index of microcirculatory resistance (IMR)
• Our aim was to assess impact of thrombus
aspiration on myocardial perfusion assessed by
IMR in patients presenting with first STEMI
5. Per protocol
analysis
Manual thrombus
aspiration
Eliminate catheter
Predilatation or
Direct stenting
Primary endpoint = significant
decrease of IMR
Patients with first STEMI
≤12h from onset of chest pain
randomization 1:1
PATA STEMI – study design
IMR
Direct stenting
or predilatation
*Thrombus aspiration catheter did not cross the lesion site and did not aspirate thrombi.
Crossover to predilatation*
**TIMI 0 or 1, or residual thrombus grade 4, or multipli thrombi persisted after predilatation.
Crossover to aspiration**
Conventional
PPCI group
Thrombus
Aspiration group
Angio
Wiring of IRA
ST
Rescue PCI
Prior MI
Prior CABG
LMCA
AV block
CPR
COPD
6. Expected IMR in conventional PPCI* = 38±20 U
Expected reduction by TA = 26% (28±20 U)
Alfa error = 5%; Power 80%
Sample size to detect difference 128 patients
Sample size calculation
*Fearon W et al., JACC, 2008
7. PATA STEMI – patient flow
RANDOMIZATION 1:1
Thrombus aspiration
(N=60)
Conventional
PCI (N=62)Coronary wire
Thrombus
aspiration
(N=66)
Predilatation
(N=30)
Stent implantation (N=68)
Direct stenting (N=58)
PTCA (N=4) TA alone (N=4)
IMR (N=76) IMR (N=52)
Coronary angiography
Stent implantation (N=51)
Direct stenting (N=21)
PTCA (N=1)
Crossover to predilatation (N=0)
Crossover to aspiration (N=10)
Final angiogram N=128
ECG at 60 min N=128
Echo ≤24h N=127 and at 4 mo N=125
Gentle predilatation (N=6)
8. Thrombus aspiration Conventional P value
(N=76) (N=52)
Clinical characteristics
Age 59,0±11,0 59,9±11,2 0,88
Male 50 (64,9%) 38 (73,1%) 0,94
Body mass index 26,8±3,86 27,9±4,56 0,41
Diabetes 9 (11,8% ) 5 (9,6%) 0,78
Hypertension 39 (51,3%) 28 (53,8%) 0,86
Hypercholesterolemia 17 (22,9%) 14 (27,4%) 0,67
Total ischemic time, min 190 (140-300) 175 (120-260) 0,12
System delay*, min 100 (65-165) 105 (65-145) 0,62
Killip class II 4 (5,2%) 3 (3,9%) 0,5
Angiographic characteristics
LAD 31 (40,8%) 22 (42,3%) 0,9
TIMI flow grade
0 or 1 60 (78,9%) 41 (78,8%) 1
2 9 (11,8%) 6 (11,5%) 1
3 7 (9,2%) 5 (9,6%) 1
Thrombus length 10.5±7.48 7.04±4.81 0,014
Baseline characteristics
*time from the first medical contact to the first balloon inflation or aspiration.
9. Thrombus aspiration Conventional P value
(N=76) (N=52)
Procedural characteristics
Fluoroscopy time 13.2±7.76 8.9±5.00 0,005
GP IIbIIIa inhibitor 24 (31,6%) 10 (19,2%) 0,15
Stent implantation 68 (89,5%) 51 (98,1%) 0,08
Stent length, mm 21,2±5,4 21,5±5,1 0,72
TIMI flow grade after wire
0 or 1 39 (51,3%) 16 (30,8%) 0,029
2 17 (22,4%) 25 (48,1%) 0,004
3 20 (26,3%) 11 (21,1%) 0,54
TIMI after TA/predilatation
0 or 1 1 (1,4%) 2 (6,7%) 0,20
2 8 (10,8%) 2 (6,7%) 0,72
3 65 (87,8%) 26 (86,6%) 1
TIMI final
2 4 (5,3%) 2 (3,8%) 1
3 72 (94,7%) 50 (96,2%) 1
Periprocedural complications
Distal embolizations* 11 (14,5%) 8 (15,4%) 0,9
Side branch occlusion 1 (1,3%) 4 (7,7%) 0,16
Procedural characteristics
*3 pts with crossover had distal embolizations (10,5 vs 21,2, P=0,09).
10. Primary endpoint
index of microcirculatory resistance
CV Tmn rest 15,3±8,9%; CV Tmn hyp 15,1±8,1%
Intention-to-treat analysis: IMR 42,4±36,1 vs. 32,0±22,4 U, P=0,020
P=0,0082
RR 32%
Per-protocol analysis
Adjacent non-IRA IMR 22,0±11,2 U vs. contralateral non-IRA IMR 25,8±17,9 U, p=0,3
11. 59.2
46.1
31.6
40.4
9.2
13.5
0% 20% 40% 60% 80% 100%
1
2
ST 70 ST 30-70 ST 30
21.1
30.8
36.8
42.3
42.1
26.9
0% 20% 40% 60% 80% 100%
1
2
MBG 0 or 1 MBG 2 MBG 3
.
. Conventional PCI
Thrombus
aspiration
Myocardial blush grade Resolution of ST-segment elevation
Percent of patients Percent of patients
MBG 0 or 1: RR 0,68 (95% CI 0,38 to 1,24; p=0,21) ST >70%: RR 1,28 (95% CI 0,91 to 1,82; p=0,16)
Angiographic and ECG signs of
myocardial reperfusion
Histopathological examination confirmed successful thrombus aspiration
in 90,8% of patients.
13. Infarct size
Median CK max
U/L
Median AUC CK
46 027
35 442
23%↓
P=0,039
24%↓
P=0,046
2414
1843
Con PPCI: IQR 114 – 7310 U/L
TA: IQR 72 – 5765 U/L
Con PPCI: IQR 5760 – 159135 U/L
TA: IQR 1395 – 108222 U/L
14. Echocardiographic analysis
LV EF
%
WMSI
49,9 48,8 51,4
54,6
6,0%↑
P=0,19
P= 0,5
P<0,0001
1,43 1,47
1,30
1,42
8,5%↓
P=0,13
P=0,0019
P= 0,9
LV EF (%); LV WMSI = wall motion score index
U
15. Clinical FU at 9 months
%
MACCE rate at 9 months
MACCE (death, reMI, stroke, CHF or TVR): Con PPCI 3 deaths (2 sudden deaths=stent thrombosis possible
and 1 stroke). 1 reSTEMI (stent thrombosis definite, TVR), 3 CHF and 3 TVR.
TA 1 death (sudden death), 1 reSTEMI, 1 CHF and 4 TVR (2 TLR).
19,6
9,2
P=0,092
13,5
3,9
P=0,045
1,9
1,3
5,8
1,3
1,9*
5,8
1,3
5,3
5,8
*1 patient had CVI and death; CHF=congestive heart failure
16. Regression model on
log-transformed IMR
Thrombus aspiration is independent predictor of lower lMR
(36,11 U; 95%CI 30,74-42,41 vs. 27,14 U; 95%CI 23,79-30,95, P=0.0076).
32%
Parameter Estimate*
95%
Lower
Limit
95%
Upper
Limit
p-value
Aspiration vs. Con. PPCI 0,7515 0,610 0,926 0,0076
DBP 1,012 1,002 1,022 0,0166
CK max (per 1000 units) 1,0888 1,013 1,170 0,0213
Age 1,0169 1,008 1,026 0,0005
*Per increase of 1 unit of the covariate, the IMR increases with the estimate as a FACTOR
17. Conclusion
• Manual thrombus aspiration reduces
microcirculatory resistance indicating improved
myocardial perfusion compared to conventional PPCI
in patients with STEMI.
• At mid term clinical follow up, the rate of hard
adverse cardiac events is lower in thrombus
aspiration group compared to conventional PPCI
group.
• Further studies powered for clinical outcomes are
needed to confirm significance of our findings.
18. Cath Lab Staff
Dejan Orlic
Goran Stankovic
Branko Belelsin
Milan Dobric
Milorad Zivkovic
Miodrag Ostojic
Study investigators
Coronary
physiology
Dejan Orlic
Miodrag Ostojic
Branko Beleslin
Milan Dobric
ECG analysis
Vladan Vukcevic
Milorad Zivkovic
Dejan Orlic
Echo analysis
Milorad Tesic
Danijela Zamaklar
Histopathologic
analysis
Milica Borovic
Data monitoring
and analysis
Goran Stankovic
Dejan Milasinovic
Dejan Orlic
Angiographic
analysis
Sinisa Stojkovic
Vladan Vukcevic
Milan Nedeljkovic
Dejan Orlic
SPECT
Dragana Sobic-
Saranovic
Cardiology clinic, Institute for histology, Institute for nuclear medicine
Clinical center of Serbia, School of medicine, University of Belgrade
21. IMR and MACCE rate
%
MACCE rate at 9 months
12,7
3,1
P=0,045
Median IMR 30,7 U
15,9
10,9
P=0,41
22. • Consecutive patients aged > 18 years
• First STEMI (≥ 2 mm of ST-segment elevation in
≥ 2 contiguous leads)
• Total ischemic time <12h
• Hemodynamic stability
INCLUSION CRITERIA
24. PATA STEMI
Thrombus
Aspiration
N = 66
Conventional
PCI
N = 62
Crossover
N = 10
Thrombus
Aspiration
N = 76
Conventional
PCI
N = 52
Crossover to aspiration: TIMI 0 or 1 after balloon inflation or thrombus >2 vessel diameter
Primary Endpoint = significantly decreased index of microcirculatory resistance
Patients with first STEMI
≤12h from onset of chest pain
Randomization 1:1
Predilatation
N = 6
25. Background
IMR= 63x0,20=12,6 U
CV Tmn bas= 12,9 %
CV Tmn hyp= 7,9 %
Rmyo= ∆P/F= Pd-Pv/1/Tmn
F≈1/Tmn
Pv≈0 mmHg
IMR= Pd x Tmn
Tmean= 3 boluses of saline at room t injected
into coronary artery during max hyperemia.
Specific, reproducible measure of
coronary microcirculatory status
less subject to hemodynamic
variation (changes in heart rate,
blood pressure, and cardiac
contractility).
26. Primary endpoint
• significant decrease of IMR
End points
Secondary endpoints
• blush grade
• ST-segment resolution
• infarct size by enzyme release
• LV remodeling indices by echo
• MACCE rate at 9 months
27. Cath Lab Staff
Dejan Orlic
Branko Belelsin
Goran Stankovic
Milan Dobric
Milorad Zivkovic
Study investigators
Coronary
physiology
Dejan Orlic
Branko Beleslin
Milan Dobric
ECG analysis
Vladan Vukcevic
Milorad Zivkovic
Dejan Orlic
Echo analysis
Milorad Tesic
Danijela Zamaklar
Histopathologic
analysis
Milica Borovic
Data monitoring
and analysis
Dejan Orlic
Dejan Milasinovic
Goran Stankovic
Angiographic
analysis
Vladan Vukcevic
Sinisa Stojkovic
Milan Nedeljkovic
Dejan Orlic
SPECT
Dragana Sobic-
Saranovic
Cardiology clinic, Institute for histology, Institute for nuclear medicine
Clinical center of Serbia, School of medicine, University of Belgrade